ConvaTec has announced the launch in Canada of a new web site, www.Hydrofiber.ca, demonstrating how the company’s proprietary Hydrofiber(R) Technology is transforming wound care. Designed for clinicians managing chronic and acute wounds, the web site illustrates the unique features and benefits of Hydrofiber(R) Technology with extensive video, data and commentary from research scientists within ConvaTec Wound Therapeutics. This transformational technology, unique to ConvaTec, powers the performance of advanced wound care products.

For the full story, Click Here

Cohera Medical Inc. has announced the treatment of the first patient in a study of its lead surgical adhesive product, TissuGlu®. The clinical investigation is a prospective, open-label, randomized study to investigate the safety of TissuGlu and its effect on wound drainage and associated complications in abdominoplasty, or “tummy tuck,” surgeries. The study will compare standard wound closure techniques to standard wound closure techniques plus the application of TissuGlu in 40 patients.

For the full story, Click Here

Synergetics USA, Inc. has announced the signing of an addendum to its three year agreement with Codman & Shurtleff, Inc. Under the terms of the revised agreement, Codman will have the exclusive right to market and distribute a Spetzler-Malis branded disposable bipolar forceps produced by Synergetics. This arrangement supports their ongoing efforts to reduce commercial expenses associated with our neurosurgery product lines.

A new platinum-based stent, designed by Boston Scientific, has received its CE Mark and will now be available in the relevant countries. The PROMUS Element Everolimus-Eluting Coronary Stent System was granted approval by the Dutch notified body KEMA Quality BV. In addition to featuring a platinum chromium alloy designed specifically for coronary stenting, the system has an innovative stent structure and an impressive catheter delivery mechanism.